newswirelogo

  • BOSTON, Sept. 23, 2020 (GLOBE NEWSWIRE) -- DraftKings Inc. (Nasdaq: DKNG) today announced that the Company’s Board of Directors (the “Board”) has appointed Jocelyn Moore and Valerie Mosley as new directors effective as of September 23, 2020. Ms. Moore and Ms. Mosley fill two newly created seats on the Board, which will now consist of 15 members. The new board appointments follow DraftKings’ recent announcement that Michael Jordan, NBA Hall of Fame inductee, six-time NBA Finals MVP and Chairman of Hornets Sports & Entertainment, will serve as a Special Advisor to the Board.

  • Company Advances Second Cardiac Myosin Inhibitor
    Company Advances Second Cardiac Myosin Inhibitor
  • Data Reported at EASD Virtual Conference Demonstrate that TTP399 Did Not Increase Plasma or Urine Ketones, Avoiding a Key Limitation to the Development of Oral Adjunctive Therapies for T1D
    Data Reported at EASD Virtual Conference Demonstrate that TTP399 Did Not Increase Plasma or Urine Ketones, Avoiding a Key Limitation to the Development of Oral Adjunctive Therapies for T1D
  • ST. PETERSBURG, FL, Sept. 23, 2020 (GLOBE NEWSWIRE) -- Global Technologies, Ltd (OTC Pink: GTLL), a holding corporation, which through its subsidiaries, has operations engaged in the online sales of CBD and hemp related products, the acquisition of intellectual property in the safety and security space and as a portal for entrepreneurs to provide immediate access to live shopping, e-commerce, product placement in brick and mortar retail outlets and logistics is pleased to announce that the Company has taken steps to expand its revenue stream through an acquisition and vendor approval.

  • ROCKVILLE, MD, Sept. 23, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced the publication of a manuscript in Molecular Cancer Therapeutics,a journal of the American Association for Cancer Research, highlighting the development of MGC018, the Company’s investigational antibody-drug conjugate (ADC) targeting B7-H3 for the treatment of solid tumors.

Contact Us

Construction Today Magazine

Cringleford Business Centre
Intwood Road
Cringleford, Norwich, UK
NR4 6AU

Click here for a full list of contacts.

Back To Top